Scalable, high titer production of AAV in the Gibco CTS AAV_Max production system
Sponsor
AAV manufacturing challenges have been extensively discussed for several years. With a limited biological understanding of recombinant vector production and the limited amount of time developers have to optimize, scale, and qualify their manufacturing process, flexible solutions that can adapt to several vectors, cell lines, or facilities are needed. Thermo Fisher Scientific has answered this need with systems, reagents, and equipment that meet the needs of this fast-moving industry.
During part one of this two-part webinar series, Jon Zmuda will present the upstream workflow of AAV production including cell culture, transfection, viral production and AAV extraction with the CTS™ AAV-MAX Helper Free AAV Production System. Specifically, we will cover:
- The ability of CTS AAV-MAX to enable scalable, high-titer, and simplified AAV production with limited optimization needed
- Studies that demonstrate the performance and scalability of the CTS AAV-MAX system in 50-L Thermo Scientific™ HyPerforma™ DynaDrive™ Single-Use Bioreactor
- How downstream process challenges can be addressed through optimized AAV purification
SPEAKERS
You might also like
Early-stage considerations for cell and gene therapy commercialization
Addressing regulatory guidance for HEK293 cells and AAV-based therapeutic manufacturing
Aldevron case study: validation of mRNA concentration determination using variable pathlength spectroscopy
Enabling RNA therapeutics: innovative cationic lipids to improve LNP formulation
